Here's a post in the PharmaTech Talk blog that covers a presentation given by my colleague Hikmat Bushnaq-Jostings,Technical Manager at SAFC. The talk addresses changes in the manufacturing of vaccines - particularly pandemic vaccines - and some of the associated challenges.
In general, we are beginning to see manufacturers begin to switch from non-cell culture based methods, e.g. eggs, to cell culture based manufacturing utiilizing chemically-defined media and feeds, along with use of new adjuvants in final dose forms. Change may be slower than we'd like sometimes due to economic or regulatory hurdles but it seems to be steady in its progress.
Posted by Bruce Lehr Jan 28th 2011.